Literature DB >> 15110753

Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis.

Weiwen Jiang1, Charles F Reich, Dong You, Ekamber Kandimalla, Sudhir Agrawal, David S Pisetsky.   

Abstract

Bacterial DNA and synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs (CpG DNA) can potently stimulate innate immunity. While the actions of CpG DNA resemble those of LPS, these molecules stimulate distinct Toll-like receptors as well as cell types. In a previous study, we showed that a CpG ODN could induce cytokine production but, unlike LPS, did not induce thymocyte apoptosis. In this study, we have further investigated these differences using as a model a second-generation immunostimulatory oligonucleotide called HYB2048. Following administration to normal BALB/c mice, HYB2048-induced IL-12 but not IL-6 production. Under conditions in which LPS induced thymocyte apoptosis, HYB2048 did not cause significant cell death and, furthermore, did not block apoptosis induced by LPS. The levels of corticosterone induced by HYB2048 were also significantly lower than those induced by LPS. This pattern of activation could distinguish CpG DNA from LPS in its effects on the immune system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110753     DOI: 10.1016/j.bbrc.2004.04.001

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Behavioral and endocrine effects of pUC19 plasmid DNA in mice.

Authors:  A I Garms; M A Zenkova; M P Moshkin; V V Vlasov
Journal:  Dokl Biol Sci       Date:  2008 Nov-Dec

2.  CpG-C immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: potential implications for clinical use.

Authors:  Yael Goldfarb; Ben Levi; Liat Sorski; Dan Frenkel; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2010-07-23       Impact factor: 7.217

3.  Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease.

Authors:  Bianca E Suur; Melody Chemaly; Moritz Lindquist Liljeqvist; Djordje Djordjevic; Markus Stenemo; Otto Bergman; Eva Karlöf; Mariette Lengquist; Jacob Odeberg; Eva Hurt-Camejo; Per Eriksson; Daniel F J Ketelhuth; Joy Roy; Ulf Hedin; Michael Nyberg; Ljubica Matic
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.